» Articles » PMID: 29599518

Psychological Outcomes and Surgical Decisions After Genetic Testing in Women Newly Diagnosed with Breast Cancer with and Without a Family History

Abstract

In patients with early breast cancer, personal and tumour characteristics other than family history are increasingly used to prompt genetic testing to guide women's cancer management (treatment-focused genetic testing, 'TFGT'). Women without a known strong family history of breast and/or ovarian may be more vulnerable to psychological sequelae arising from TFGT. We compared the impact of TFGT in women with (FH+) and without (FH-) a strong family history on psychological adjustment and surgical decisions. Women aged <50 years with high-risk features were offered TFGT before definitive breast cancer surgery and completed self-report questionnaires at four time points over 12 months. All 128 women opted for TFGT. TFGT identified 18 carriers of a disease-causing variant (50.0% FH+) and 110 non-carriers (59.1% FH+). There were no differences based on family history in bilateral mastectomy (BM) uptake, p = .190, or uptake of risk-reducing bilateral salpingo-oophorectomy (RRBSO), p = .093. FH- women had lower decreases in anxiety a year after diagnosis, p = .011, and regret regarding their decision whether to undergo BM, p = .022, or RRBSO, p = .016 than FH + women. FH- carriers reported significantly higher regret regarding their TFGT choice (p = .024) and test-related distress (p = .012) than FH + carriers, but this regret/distress could not be attributed to a concern regarding a possible worse prognosis. These findings indicate that FH- women may require additional counselling to facilitate informed decisions. Carriers without a family history may require additional follow-up counselling to facilitate psychological adjustment to their positive variant results, extra support in making surgical decisions, and counselling about how best to communicate results to family members.

Citing Articles

Adjuvant vs. neoadjuvant chemotherapy: quality of life and psychosocial variables in women with breast cancer.

Santos A, Silva I, Guimaraes R, Meneses R Health Psychol Rep. 2023; 11(1):59-69.

PMID: 38084348 PMC: 10679916. DOI: 10.5114/hpr/152329.


Universal genetic testing for women with newly diagnosed breast cancer in the context of multidisciplinary team care.

De Silva D, Stafford L, Skandarajah A, Sinclair M, Devereux L, Hogg K Med J Aust. 2023; 218(8):368-373.

PMID: 37005005 PMC: 10952347. DOI: 10.5694/mja2.51906.


Heterogeneity of posttraumatic stress, depression, and fear of cancer recurrence in breast cancer survivors: a latent class analysis.

Malgaroli M, Szuhany K, Riley G, Miron C, Park J, Rosenthal J J Cancer Surviv. 2022; 17(5):1510-1521.

PMID: 35224684 PMC: 10037701. DOI: 10.1007/s11764-022-01195-y.


Psychosocial outcome and health behaviour intent of breast cancer patients with BRCA1/2 and PALB2 pathogenic variants unselected by a priori risk.

Padmanabhan H, Hassan N, Wong S, Lee Y, Lim J, Hasan S PLoS One. 2022; 17(2):e0263675.

PMID: 35167615 PMC: 8846504. DOI: 10.1371/journal.pone.0263675.


Patient-Reported Outcomes following Genetic Testing for Familial Hypercholesterolemia, Breast and Ovarian Cancer Syndrome, and Lynch Syndrome: A Systematic Review.

Hendricks-Sturrup R, Joseph L, Lu C J Pers Med. 2021; 11(9).

PMID: 34575627 PMC: 8467628. DOI: 10.3390/jpm11090850.


References
1.
Bradbury A, Patrick-Miller L, Long J, Powers J, Stopfer J, Forman A . Development of a tiered and binned genetic counseling model for informed consent in the era of multiplex testing for cancer susceptibility. Genet Med. 2014; 17(6):485-92. PMC: 4983405. DOI: 10.1038/gim.2014.134. View

2.
Schlich-Bakker K, Ausems M, Schipper M, ten Kroode H, Warlam-Rodenhuis C, van den Bout J . BRCA1/2 mutation testing in breast cancer patients: a prospective study of the long-term psychological impact of approach during adjuvant radiotherapy. Breast Cancer Res Treat. 2007; 109(3):507-14. PMC: 2668630. DOI: 10.1007/s10549-007-9680-y. View

3.
Thewes B, Meiser B, Hickie I . Psychometric properties of the Impact of Event Scale amongst women at increased risk for hereditary breast cancer. Psychooncology. 2001; 10(6):459-68. DOI: 10.1002/pon.533. View

4.
Cella D, Hughes C, Peterman A, Chang C, Peshkin B, Schwartz M . A brief assessment of concerns associated with genetic testing for cancer: the Multidimensional Impact of Cancer Risk Assessment (MICRA) questionnaire. Health Psychol. 2002; 21(6):564-72. View

5.
Ibbotson T, Maguire P, Selby P, Priestman T, Wallace L . Screening for anxiety and depression in cancer patients: the effects of disease and treatment. Eur J Cancer. 1994; 30A(1):37-40. DOI: 10.1016/s0959-8049(05)80015-2. View